; Texas, Arizona, and Colorado also have high rates of CCM due to the common Hispanic mutation. 3. Expansion and coordination of activities of National Institutes of Health with respect to cerebral cavernous malformations research Part B of title IV of the Public Health Service Act ( 42 U.S.C. 284 et seq.) is amended by adding at the end the following: 409K. Cerebral cavernous malformations research activities (a) Expansion and coordination of activities The Director of NIH, in coordination with the directors of the National Institute of Neurological Disorders and Stroke, the National Center for Advancing Translational Sciences, the National Heart, Lung, and Blood Institute, and other national research institutes, as appropriate, for the purpose of conducting research and related activities concerning cerebral cavernous malformations (referred to in this section as CCM )— (1) shall strengthen and coordinate efforts of the National Institutes of Health; and (2) may award grants and cooperative agreements to public or nonprofit private entities (including State health departments, political subdivisions of States, universities, and other medical or educational entities). (b) Activities The research and related activities described in subsection (a) shall include the following: (1) Clinical, translational, and basic research The Director of NIH shall conduct or support, through funding opportunity announcements, grants, or cooperative agreements, basic, clinical, and translational research on CCM, including research on— (A) the identification and development of biomarkers that fulfill the requirement of the Food and Drug Administration for biomarker qualification as proper measures of phenotypic variation; (B) safety or efficacy for new or repurposed currently approved drugs for CCM treatment; (C) research related to improving the quality of life for individuals with CCM and their families; (D) contributions of genetic variation to clinical presentation as targets for therapy